Salvage Radiation for Prostate Cancer: What to Expect

Salvage radiation therapy is the main curative option when prostate-specific antigen (PSA) levels start rising after a prostatectomy, signaling that cancer cells may still be present. For most men, the treatment involves daily trips to a radiation center over several weeks, with side effects that are generally manageable and outcomes that depend heavily on how early treatment begins. The details of what the experience looks like, from the decision to treat through long-term follow-up, involve more moving parts than many patients expect.

When Salvage Radiation Gets Recommended

After a prostatectomy, your PSA should drop to undetectable levels. If it starts creeping back up, that rise is called a biochemical recurrence. The usual trigger for salvage radiation is two consecutive PSA readings at or above 0.2 ng/mL. But the goal is to act before that number climbs much higher, ideally staying below 0.5 ng/mL. A study from the University of Frankfurt comparing early versus later salvage radiation found that men treated at a PSA below 0.5 ng/mL had dramatically better metastasis-free survival than those treated at higher levels.¹ That aligns with European guidelines recommending that salvage radiation begin at low PSA values rather than waiting for a specific threshold to be crossed.

A separate analysis confirmed that delayed salvage radiation was associated with poorer outcomes, while starting extremely early (before the 0.2 ng/mL mark) did not appear to offer a survival advantage either. The sweet spot, based on current evidence, is starting after two consecutive rising PSA values reach 0.2 ng/mL but before hitting 0.5 ng/mL.²

Adjuvant Versus Early Salvage Radiation

One question that comes up early in the decision process is whether radiation should have been given right after surgery (adjuvant radiation) rather than waiting for PSA to rise. The ARTISTIC meta-analysis, pooling data from three large randomized trials, found no meaningful difference in event-free survival between adjuvant radiation and early salvage radiation, with five-year rates of roughly 89% versus 88%.³ That result has shifted practice: many urologists and radiation oncologists now prefer to hold off on radiation after surgery and monitor PSA instead, reserving radiation for men who actually show signs of recurrence.

Not everyone agrees the question is settled. A large multi-institutional study found that among men with particularly aggressive pathology, adjuvant radiation was associated with lower all-cause mortality compared to early salvage radiation.⁴ And a separate analysis showed notably better twelve-year disease control with adjuvant treatment in patients with adverse features.⁵ So the answer may depend on your individual risk profile. For most men, though, early salvage radiation has become the preferred approach because it avoids exposing the majority of patients who are actually cured by surgery to the side effects of radiation they never needed.

The Imaging Step Before Treatment

Before radiation planning begins, your team will want to know where the cancer is. PSMA PET/CT scans have become a game-changer here. These scans use a radioactive tracer that binds to prostate cancer cells, and they can detect recurrences at remarkably low PSA levels. In one study of 90 men undergoing salvage radiation, PSMA PET detected suspicious lesions in about half of patients. Among those with positive findings, the majority had disease confined to the prostate bed (where the prostate used to be), while a smaller group had pelvic lymph node involvement.⁶

This matters practically because it can change the radiation plan. If the scan shows disease only in the prostate bed, a smaller, more focused radiation field may be appropriate. If lymph nodes light up, your radiation oncologist may recommend treating a wider area. And if the scan reveals distant spread, salvage radiation alone may not be the right strategy at all. Not every center uses PSMA PET routinely before salvage radiation yet, but it is rapidly becoming standard care.

What the Radiation Itself Looks Like

Salvage radiation to the prostate bed is delivered from outside the body using a machine called a linear accelerator. You lie on a treatment table, typically on your back, and the machine rotates around you to deliver precisely shaped beams. Each session lasts roughly 15 to 20 minutes, though the actual radiation delivery takes only a few minutes. Most of the time is spent getting you positioned correctly.

The dominant techniques today are intensity-modulated radiation therapy (IMRT) and volumetric-modulated arc therapy (VMAT). Both shape the radiation beam to conform tightly to the target while limiting dose to the bladder and rectum. A planning study found that VMAT achieved better sparing of the rectum and femoral heads compared to a seven-field IMRT plan.⁷ In practice, many centers use VMAT because it also delivers treatment faster. Early experience with salvage IMRT showed that treatment was feasible without any severe acute gastrointestinal or urinary toxicity.⁸

How Long Treatment Takes and Fractionation Options

The conventional salvage radiation course involves daily treatments (Monday through Friday) over roughly six and a half to seven weeks, delivering a total dose in the range of 64 to 70 Gy in small daily fractions. A randomized trial comparing standard fractionation to a moderately hypofractionated schedule (larger daily doses over fewer sessions) found no meaningful difference in four-year biochemical progression-free survival, which was around 80% in the shorter course and 78% in the longer one. Quality-of-life outcomes were also comparable between the two approaches.⁹ Longer-term data from another institution’s moderately hypofractionated program confirmed that the shortened course was as safe and effective as standard fractionation over a decade of follow-up.¹⁰

An even shorter option, stereotactic body radiation therapy (SBRT), delivers treatment in just five sessions using much larger daily doses. A phase II trial of prostate-bed SBRT reported five-year overall survival above 95% and low rates of severe toxicity.¹¹ A review of early SBRT experiences noted that urinary side effects at the moderate-severity level occurred in up to roughly a quarter of patients, while bowel toxicity generally remained low. The catch is that follow-up is still short, and late side effects after pelvic radiation can take years to appear.¹² SBRT for salvage radiation remains investigational at most centers, though its convenience (a week of treatment versus six or seven) makes it an appealing prospect if longer follow-up confirms safety.

Whether Pelvic Lymph Nodes Should Be Treated

A critical treatment planning decision is whether to include the pelvic lymph nodes in the radiation field or limit treatment to the prostate bed alone. The SPPORT trial, a large phase 3 randomized study, answered this directly. Men who received salvage radiation to both the prostate bed and pelvic nodes (along with short-term hormone therapy) had a five-year freedom-from-progression rate of about 87%, compared with roughly 71% for men who got prostate-bed-only radiation without hormones.¹³ The combined approach was the clear winner, though it came with more acute side effects: about 44% of patients in the combined group experienced at least moderate acute toxicity, compared with 18% for prostate-bed-only radiation. The encouraging news is that late side effects did not differ significantly between the groups.

For men with confirmed node-positive disease, the prospective PLATIN trials showed that salvage radiation to the pelvis achieved a median progression-free survival of about five and a half years, with severe late toxicity in only about 4% of patients at two years.¹⁴ An older study found a more nuanced picture: pelvic node radiation did not help on average, but among men whose PSA at the time of salvage radiation was already at or above 0.4 ng/mL, it was associated with about a 50% reduction in the risk of further PSA progression.¹⁵ The takeaway is that pelvic node treatment appears most valuable in men with higher-risk features or higher PSA at the time of salvage treatment.

Adding Hormone Therapy

Salvage radiation is increasingly given alongside androgen deprivation therapy (ADT). A systematic review and meta-analysis found that adding short-term hormone therapy (typically six months of ADT) to salvage radiation significantly improved biochemical control and metastasis-free survival.¹⁶ Long-term ADT (two years) also improved metastasis-free survival. Neither short-term nor long-term hormone therapy showed a statistically significant benefit for overall survival in the pooled analysis, though a separate review noted that the two-year duration drove improvements in metastasis-free and overall survival in individual landmark trials.¹⁷

For men with particularly high-risk recurrences, more aggressive combinations are under study. A phase 2 trial of enzalutamide (a newer hormone-blocking drug) added to salvage radiation showed that two-year freedom from progression was 84% versus 66% with placebo.¹⁸ Another trial combining apalutamide (a similar drug) with salvage radiation and chemotherapy reported a three-year progression-free survival of 71%, which compared favorably to historical results.¹⁹ These intensified regimens come with more side effects, though, so the conversation with your oncologist will weigh the aggressiveness of your recurrence against the added burden of treatment.

Side Effects During Treatment

The most common acute side effects are urinary frequency, urgency, and mild rectal irritation. These typically build over the course of treatment and peak in the final weeks. The SAKK 09/10 trial, which randomized men between 64 Gy and 70 Gy, offers useful benchmarks. At the lower dose, about 13% of men experienced moderate urinary toxicity and 16% moderate bowel toxicity during treatment. At the higher dose, the rates were slightly higher, around 17% and 15% respectively. Severe acute toxicity was uncommon at both dose levels, occurring in fewer than 3% of patients.²⁰ Men receiving the higher dose reported a more noticeable worsening of urinary symptoms. Fatigue is also common, though usually mild.

These acute effects generally resolve within a few weeks of finishing treatment. Most men are able to continue working and going about daily routines during salvage radiation, though some adjust their schedules around the daily treatment appointments and the occasional bad day.

Late Side Effects and Long-Term Function

Late side effects, appearing months to years after treatment, are the bigger concern. A study tracking patients after postprostatectomy radiation found that at five years, about 10% had developed moderate late urinary toxicity and about 4% had moderate late bowel issues. Severe late toxicity was rare, at roughly 1% for urinary and under 1% for bowel problems.²¹ Urethral stricture and bladder neck narrowing can also occur, particularly given the combination of surgical changes and radiation. Most of these respond to minimally invasive procedures like dilation, though truly stubborn cases may require more involved reconstruction.

Erectile function is a legitimate worry. Many men already have erectile dysfunction after prostatectomy, and radiation adds to that challenge. One study found that three-year erectile recovery rates were about 35% in men who received no radiation, 29% for those who had salvage radiation, and only about 12% for men who received adjuvant radiation immediately after surgery. Waiting at least a year after surgery before starting radiation was associated with much better functional recovery.²² A longer-term analysis from the SAKK 09/10 trial confirmed that while salvage radiation did affect erectile function further, higher radiation doses did not make it significantly worse than lower doses.²³ Salvage radiation patients also reported significantly poorer recovery in urinary, bowel, and sexual function compared to their baseline, with urinary and sexual function showing clinically meaningful declines.²⁴

Protecting the Rectum With Hydrogel Spacers

One strategy for reducing bowel side effects is the placement of a hydrogel spacer between the rectum and the area being treated. This is a gel injected through the perineum (the space between the scrotum and rectum) that physically pushes the rectal wall away from the radiation target, reducing the dose the rectum receives. While hydrogel spacers are well-established for primary prostate radiation, using them in the salvage setting is trickier because surgery has already altered the anatomy and may have created scar tissue. Case reports have demonstrated that the spacer can be placed safely even in post-surgical patients, including those who had prior focal treatments, and that radiation can then be completed without early complications.²⁵ The spacer gradually dissolves on its own over several months. It is not universally offered, but if rectal sparing is a particular concern, it is worth discussing with your radiation oncologist.

Genomic Testing and Risk Stratification

Not all biochemical recurrences carry the same level of danger, and genomic tests are increasingly used to figure out which men need more aggressive treatment and which can be managed with radiation alone. The Decipher genomic classifier, a 22-gene test run on the tissue removed during prostatectomy, has been validated as a tool to help stratify risk. In an analysis linked to the NRG/RTOG 9601 trial, Decipher was identified as a promising biomarker for guiding hormone therapy decisions alongside salvage radiation.²⁶

Newer signatures go beyond a single score. Research from the STREAM trial found that men whose tumors had signatures of specific genetic losses had worse progression-free survival, while those whose tumors showed a strong predicted response to hormone therapy did better.²⁷ RNA expression tests more broadly have gained traction for enabling tailored treatment decisions in the salvage setting.²⁸ In practice, this means that if you are facing salvage radiation, your oncologist may order a genomic test on your prostatectomy specimen to help decide whether hormone therapy should be added, and for how long.

How You Will Know If It Is Working

After salvage radiation, you will continue regular PSA monitoring. A dropping PSA during and after treatment is a strong positive sign. In one study of 185 men, about three-quarters saw their PSA drop during salvage radiation, and 71% of those men had disease control at two years. Among the roughly one-quarter whose PSA stayed flat or rose during treatment, only about 24% achieved two-year control.²⁹ A separate prospective study with about five years of follow-up confirmed that the rate at which PSA falls during treatment was the strongest predictor of long-term disease control, with five-year failure-free survival around 56% across the whole cohort.³⁰

The PSA typically continues to decline for several months after radiation ends, so a single post-treatment value is not definitive. Your doctor will track the trend over multiple readings, usually every three to six months. A PSA that reaches an undetectable level and stays there is the best possible outcome. A slow, steady decline that plateaus at a low level is also often acceptable. A rising trend after an initial decline, or a PSA that never falls, usually signals persistent or resistant disease and prompts a conversation about next steps.

When Salvage Radiation Is Given a Second Time

A less common but increasingly studied scenario is re-irradiation: delivering a second course of radiation to the prostate bed after a prior course has failed. This is not the same as initial salvage radiation after surgery; it involves re-treating tissue that has already been irradiated, which carries a higher risk of complications because tissues retain a “memory” of prior radiation damage. Small series using SBRT for re-irradiation of the prostate bed have reported encouraging early disease control with acceptable toxicity.³¹ In one multicenter retrospective study, salvage SBRT re-irradiation for local recurrence in the prostate bed achieved a median progression-free survival of about two years, with roughly 18% of patients experiencing moderate or worse late urinary or bowel toxicity at three years.³² Hydrogel spacers can play a particularly valuable role in this setting, creating extra distance between previously irradiated rectal tissue and the new radiation target. Re-irradiation remains a specialized decision, typically made at centers with expertise in SBRT planning, and is reserved for men with biopsy-confirmed local recurrence and limited options.